Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABBV Stock Forecast 2025-2026
$225.18
Current Price
$394.11B
Market Cap
Buy 20
Hold 9
Sell 1
Wall St Analyst Ratings
Distance to ABBV Price Targets
+28.3%
To High Target of $289.00
+8.8%
To Median Target of $245.00
-18.3%
To Low Target of $184.00
ABBV Price Momentum
-1.5%
1 Week Change
+0.0%
1 Month Change
+29.1%
1 Year Change
+26.7%
Year-to-Date Change
-8.0%
From 52W High of $244.81
+37.0%
From 52W Low of $164.39
📊 TOP ANALYST CALLS
Did ABBV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AbbVie is one of their latest high-conviction picks.
Latest ABBV Stock Price Targets & Analyst Predictions
Based on our analysis of 44 Wall Street analysts, ABBV has a bullish consensus with a median price target of $245.00 (ranging from $184.00 to $289.00). The overall analyst rating is Strong Buy (8.1/10). Currently trading at $225.18, the median forecast implies a 8.8% upside. This outlook is supported by 20 Buy, 9 Hold, and 1 Sell ratings.
The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 28.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABBV Analyst Ratings
20
Buy
9
Hold
1
Sell
ABBV Price Target Range
Low
$184.00
Average
$245.00
High
$289.00
Current: $225.18
Latest ABBV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABBV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 7, 2025 | UBS | Ashwani Verma | Neutral | Maintains | $220.00 |
| Nov 5, 2025 | Piper Sandler | David Amsellem | Overweight | Reiterates | $289.00 |
| Nov 3, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $260.00 |
| Nov 3, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $235.00 |
| Oct 20, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $242.00 |
| Oct 17, 2025 | Raymond James | Gary Nachman | Outperform | Reiterates | $250.00 |
| Oct 10, 2025 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $284.00 |
| Oct 9, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Oct 3, 2025 | B of A Securities | Geoff Meacham | Neutral | Maintains | $251.00 |
| Oct 1, 2025 | HSBC | Rajesh Kumar | Hold | Downgrade | $N/A |
| Sep 22, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $222.00 |
| Sep 17, 2025 | Berenberg | Luisa Hector | Buy | Upgrade | $270.00 |
| Sep 16, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $235.00 |
| Sep 15, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Maintains | $245.00 |
| Sep 12, 2025 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $240.00 |
| Sep 12, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $260.00 |
| Aug 13, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Aug 12, 2025 | Piper Sandler | David Amsellem | Overweight | Assumes | $231.00 |
| Aug 1, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $227.00 |
| Aug 1, 2025 | Raymond James | Gary Nachman | Outperform | Maintains | $236.00 |
AbbVie Inc. (ABBV) Competitors
The following stocks are similar to AbbVie based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AbbVie Inc. (ABBV) Financial Data
AbbVie Inc. has a market capitalization of $394.11B with a P/E ratio of 170.2x. The company generates $59.64B in trailing twelve-month revenue with a 4.0% profit margin.
Revenue growth is +9.1% quarter-over-quarter, while maintaining an operating margin of +35.5% and return on equity of +138.0%.
Valuation Metrics
Market Cap
$394.11B
Enterprise Value
$462.79B
P/E Ratio
170.2x
PEG Ratio
-1.9x
Price/Sales
6.6x
Growth & Margins
Revenue Growth (YoY)
+9.1%
Gross Margin
+66.4%
Operating Margin
+35.5%
Net Margin
+4.0%
EPS Growth
-88.1%
Financial Health
Cash/Price Ratio
+1.4%
Current Ratio
0.7x
Debt/Equity
-26.5x
ROE
+138.0%
ROA
+9.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AbbVie Inc. (ABBV) Business Model
About AbbVie Inc.
What They Do
Biopharmaceutical company focusing on innovative therapies.
Business Model
AbbVie generates revenue through the discovery, development, and marketing of pharmaceutical products, primarily in immunology, oncology, neuroscience, and virology. The company profits from a diverse portfolio of patented medications, which includes high-demand drugs like Humira and newer offerings from strategic acquisitions such as Allergan.
Additional Information
Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie is committed to expanding its therapeutic areas and product pipeline through acquisitions and innovation. The company's focus on addressing complex and chronic health conditions positions it strongly in the healthcare market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
55,000
CEO
Mr. Robert A. Michael CPA
Country
United States
IPO Year
2013
Website
www.abbvie.comAbbVie Inc. (ABBV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
Dec 09, 2025
By Aparajita Dutta
ETF News and Commentary
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.
Dec 08, 2025
By Zacks Equity Research
Tale of the Tape
Top-Ranked ETFs to Power Your Portfolio Higher
With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.
Dec 08, 2025
By Yashwardhan Jain
ETF News and Commentary
Latest News
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development
3 days ago
Quick Summary
OSE Immunotherapeutics has amended its partnership with AbbVie, regaining early-stage control of ABBV-230, a monoclonal antibody for inflammation, while AbbVie retains future development rights post-Phase 1.
Why It Matters
OSE Immunotherapeutics regaining early-stage control of ABBV-230 may enhance its innovation potential and valuation, signaling strength in its partnership with AbbVie, which could impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AbbVie (ABBV) closed at $223.12, marking a decline of 1.31% from the previous day's closing price.
Why It Matters
AbbVie's decline of 1.31% may signal weakening investor confidence or market reactions to company news, potentially impacting future stock performance and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
3 Top Dividend Stocks to Buy in December
1 day ago
Quick Summary
AbbVie is a Dividend King noted for its resilience, while Ares Capital provides an ultra-high yield with strong growth potential both near-term and long-term.
Why It Matters
AbbVie's status as a Dividend King signals stability and reliability, appealing to income-focused investors. Ares Capital's high yield coupled with growth potential attracts those seeking strong returns.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Eli Lilly's GLP-1 drug is now the top-selling drug globally in Q3. Merck, Johnson & Johnson, and AbbVie are also experiencing growth from new or existing drugs.
Why It Matters
Eli Lilly's success with its GLP-1 drug signals strong market demand, potentially boosting investor confidence in the pharmaceutical sector and highlighting competitive dynamics among major companies.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
AbbVie has shown strong performance over the past 12 years, maintaining key traits that contributed to its success.
Why It Matters
AbbVie's strong historical performance and retention of key traits suggest continued stability and growth potential, which can influence investment decisions positively.
Source: The Motley Fool
Market Sentiment:
Neutral
The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
4 days ago
Quick Summary
AbbVie reported third-quarter results that surpassed Wall Street expectations, driven by significant sales growth from its three leading drugs.
Why It Matters
AbbVie's strong Q3 results and rising sales of key drugs signal robust financial health, potentially boosting stock performance and attracting investor confidence.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About ABBV Stock
What is AbbVie Inc.'s (ABBV) stock forecast for 2026?
Based on our analysis of 44 Wall Street analysts, AbbVie Inc. (ABBV) has a median price target of $245.00. The highest price target is $289.00 and the lowest is $184.00.
Is ABBV stock a good investment in 2026?
According to current analyst ratings, ABBV has 20 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $225.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABBV stock?
Wall Street analysts predict ABBV stock could reach $245.00 in the next 12 months. This represents a 8.8% increase from the current price of $225.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AbbVie Inc.'s business model?
AbbVie generates revenue through the discovery, development, and marketing of pharmaceutical products, primarily in immunology, oncology, neuroscience, and virology. The company profits from a diverse portfolio of patented medications, which includes high-demand drugs like Humira and newer offerings from strategic acquisitions such as Allergan.
What is the highest forecasted price for ABBV AbbVie Inc.?
The highest price target for ABBV is $289.00 from David Amsellem at Piper Sandler, which represents a 28.3% increase from the current price of $225.18.
What is the lowest forecasted price for ABBV AbbVie Inc.?
The lowest price target for ABBV is $184.00 from at , which represents a -18.3% decrease from the current price of $225.18.
What is the overall ABBV consensus from analysts for AbbVie Inc.?
The overall analyst consensus for ABBV is bullish. Out of 44 Wall Street analysts, 20 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $245.00.
How accurate are ABBV stock price projections?
Stock price projections, including those for AbbVie Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 2:01 AM UTC